Previous Article | Next Article 
Journal of Clinical Microbiology, September 2001, p. 3339-3345, Vol. 39, No. 9
Institute of Microbiology, Tartu
University,1 and Tartu University Lung
Hospital, Clinicum,4 Tartu, and
Kivimäe Hospital, Tallinn,5
Estonia, and Microbiology and Tumor Biology Center, Karolinska
Institute,2 and Swedish Institute for
Infectious Disease Control,3 Stockholm, and
Department of Bacteriology, Biomedicum, Swedish University for
Agricultural Sciences, Uppsala,6 Sweden
Received 27 February 2001/Returned for modification 16 April
2001/Accepted 15 June 2001
Restriction fragment length polymorphism (RFLP) analysis of 209 Mycobacterium tuberculosis clinical isolates obtained from newly detected pulmonary tuberculosis patients (151 male and 58 female;
mean age, 41 years) in Estonia during 1994 showed that 61 isolates
(29%) belonged to a genetically closely related group of isolates,
family A, with a predominant IS6110 banding pattern. These
strains shared the majority of their IS6110 DNA-containing restriction fragments, representing a predominant banding pattern (similarity, >65%). This family A comprised 12 clusters of identical isolates, and the largest cluster comprised 10 strains. The majority (87.5%) of all multidrug-resistant (MDR) isolates, 67.2% of all isolates with any drug resistance, but only 12% of the fully
susceptible isolates of M. tuberculosis belonged to family
A. These strains were confirmed by spoligotyping as members of the
Beijing genotype family. The spread of Beijing genotype MDR M. tuberculosis strains was also frequently seen in 1997 to 1999. The members of this homogenous group of drug-resistant M. tuberculosis strains have contributed substantially to the
continual emergence of drug-resistant tuberculosis all over Estonia.
An increase in tuberculosis (TB)
morbidity accompanied by an appearance of multidrug-resistant (MDR) TB
has been documented in Estonia since the early 1990s. After a decline
in incidence from 417 per 100,000 population in 1953 to 26 per 100,000 in 1992, the incidence showed a steady increase, which reached 52 per
100,000 in 1999 (26). This twofold increase in morbidity
was accompanied by an increase in drug-resistant TB and particularly in
MDR TB (i.e., TB that is resistant to at least isoniazid and rifampin) and has become a serious problem in Estonia. In 1994 and 1998, MDR TB
comprised 10% (13) and 14% (25) of the new
pulmonary cases detected. This places Estonia among the countries with
the highest MDR TB rates in the world (24).
To understand the epidemiology of tuberculosis, molecular methods such
as restriction fragment length polymorphism (RFLP) analyses of the
infecting organisms have proven to be very powerful tools (11,
20, 27). The RFLP method can detect genotypic variations between
strains by using repetitive DNA sequences as probes in Southern
hybridization analyses (12).
In outbreak investigations (1, 14, 16), mutual association
of IS6110 RFLP patterns and resistance profiles has often been described. However, in population-based studies, the molecular epidemiology and drug resistance pattern of the M. tuberculosis isolates (constituting a genetically closely related
group of bacteria) have been studied only in very few geographical
settings (23).
In the epidemiology of drug-resistant disease, molecular
epidemiological studies of resistant strains could help identify current and past failures in TB control and allow tracking of the
transfer path of the resistant strains (6). In this study we explore the spread of M. tuberculosis strains in Estonia
by molecular epidemiological methods and demonstrate that transmission of several highly related clones of drug-resistant M. tuberculosis strains contributes to the emergence of
drug-resistant TB all over Estonia.
The Estonian TB Register was the source of demographic data and
clinical information on the patients. The majority of TB patients were
diagnosed and treated at either of two lung hospitals, Tartu University
Lung Hospital in Tartu (South Estonia) or Kivimäe Hospital in
Tallinn (North Estonia). In 1994, 518 patients (355 men and 163 women;
mean age, 41 years) were reported to have newly detected TB cases,
i.e., with no previous history of tuberculosis. Of the 518 newly
detected pulmonary TB patients, 299 (63%) had cases that were smear
and/or culture positive.
Patients.
In 1994, 209 (70%) of 299 isolates were available
for IS6110 RFLP typing. The mean age of the 209 patients who
were included in the study was 41 years; 151 (72%) were male (mean
age, 42 years), and 58 (28%) were female (mean age, 39 years). There
was no significant difference in age and sex distribution between these
209 patients with pulmonary TB and the 518 patients reported as the
total of newly detected cases in 1994.
Characterization of mycobacterial isolates.
The analyzed
M. tuberculosis strains were isolated at the Tuberculosis
Laboratory in Tallinn (central laboratory for the North Estonia) and
the National Reference Laboratory (NRL) in Tartu. The species
identification of the isolates was based on standard microbiological
tests: colony morphology, acid-fast staining, and biochemical tests
(10). It was confirmed by a DNA-RNA hybridization technique (AccuProbe; GenProbe Inc., San Diego, Calif.) at the Swedish
Institute for Infectious Disease Control (SMI) in Stockholm, Sweden.
Drug susceptibility testing.
Drug susceptibility testing of
all isolates was performed both in Estonia and in Sweden. In Estonia it
was done by conventional culturing on solid media using the
proportion method (4), and at SMI it was done using
radiometric respirometry with the Bactec system (18). This
method is in good agreement with the resistance ratio method on
Löwenstein-Jensen medium (9). The TB laboratory at
SMI is part of the network of Supranational Reference Laboratories for
drug susceptibility testing of M. tuberculosis, initiated by
the World Health Organization (15), and serves as an
external reference laboratory for Estonia. The drugs tested included
streptomycin (4 mg/liter), isoniazid (0.2 mg/liter), ethambutol (5 mg/liter), and rifampin (2 mg/liter).
RFLP analyses.
Extraction of DNA from mycobacterial strains
and DNA fingerprinting with IS6110 as a probe were performed
by standardized methods (20) at SMI. In brief, after 3 to
4 weeks of growth on Löwenstein-Jensen medium, the bacteria were
harvested and heat killed (80°C for 20 min). DNA was extracted and
digested with PvuII. After electrophoresis of the digested
DNA on an agarose gel, the 245-bp sequence of IS6110 was
chemiluminescence labeled. The gels were scanned and the results were
analyzed by computer with the Gelcompar software (Applied Maths,
Kortrijk, Belgium) as described previously (7).
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.9.3339-3345.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Spread of Drug-Resistant Pulmonary Tuberculosis
in Estonia
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
65% (sharing more than two-thirds
of the IS-containing PvuII fragments) (12, 20)
are defined as belonging to a family of strains. Clinical isolates with
identical IS6110 RFLP pattern constituted one cluster.
Spoligotyping. The spoligotyping method, with a slightly lower level of discrimination than that of IS6110-RFLP typing (1, 12), was used as an additional tool for determining relationships among the isolates belonging to family A (21). The DR locus in the M. tuberculosis complex genome contains multiple, highly conserved 36-bp direct repeats (DR). The repeats are separated by 35- to 41-bp spacer sequences, which are variable. The analysis of this locus by spoligotyping is based on the fact that the separate spacer sequences are unique and can be hybridized to synthetic spacer oligonucleotides that are bound to a membrane. The hybridization pattern will then show which spacer oligonucleotides are present in each strain (11). The DR-based fingerprint is a good secondary marker to support or rule out strain clustering. A total of 37 isolates with different RFLP patterns were selected for spoligotyping, according to the similar distribution of different families, clones, and nonrelated strains in the investigated samples. Purified chromosomal DNA from RFLP typing was available. Membranes for spoligotyping were obtained from Isogen, Bioscience BV, Utrecht, The Netherlands. The membranes contained oligonucleotides derived from the spacer DNA sequences, interspersed with the directly repeated sequences in the DR region of M. tuberculosis strain H37RV and M. bovis BCG. The presence or absence of these spacers in M. tuberculosis complex strains can be detected by hybridization of the amplified DNA of these spacer regions by using primers complementary to the DR. PCR and hybridization were performed as previously described (11).
Statistics.
Data analysis was performed using the Statistica
program. Subject variables were examined using the 
2
test of association for categorical variables and t test for continuous variables. A P value of <0.05 was used to
indicate statistical significance.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
IS6110 fingerprints in the study population. The 209 M. tuberculosis isolates were characterized by IS6110 RFLP analysis. The number of IS6110 copies per isolate varied between 5 and 19 (mean, 12 bands). The majority, i.e., 195 (93%) of the isolates, contained 8 to 17 copies, with a mean of 12 bands.
M. tuberculosis isolates of 102 of the 209 patients (49%) belonged to different clusters, while 107 (51%) clinical isolates presented unique (individual) RFLP fingerprint patterns. A total of 140 isolates (67%) (44 with unique patterns and 96 with clustered ones) could be allocated into five major families on the basis of their RFLP patterns (65% similarity), families A to E (Fig.
1). The largest family, family A,
comprised 61 isolates in 12 clusters, with largest cluster comprising
10 closely related or identical isolates (Table
1). Of the 209 patients, 47 (22%) were
infected with isolates belonging to families B to E, and 34 (16%)
isolates belonged to 12 clusters outside the five major families (Fig.
1; Table 1).
|
|
Correlation between IS6110 RFLP patterns and drug resistance. Of the 209 M. tuberculosis isolates, 64 (31%) were resistant to one or more of the drugs tested while 24 (11.5%) of them were multidrug resistant (MDR), i.e., resistant to both isoniazid and rifampin.
There was a remarkable homogeneity in RFLP banding patterns in drug-resistant isolates, with the majority belonging to family A (Fig. 2). Family A (n = 61) comprised 21 MDR isolates and 43 isolates with any drug resistance. The other families contained only 2 of 24 MDR isolates (8.3%) and 10 of 64 isolates with any drug resistance (15.6%) (Table 1). Among isolates that were not clustered or did not belong to any of the five families, only 1 of 24 MDR (4.2%) and 64 of 145 fully susceptible (44%) isolates were found.
|
Genetic homogenity of family A confirmed by spoligotyping.
The
12 strains from family A showed an identical and unusual
spoligopattern, lacking spacers 1 to 34. This pattern is consistent with the spoligotype pattern of the so-called Beijing genotype M. tuberculosis strains (21).
The spoligotypes of the non-Beijing family strains were highly diverse (Table 2).
|
Patient characteristics in relation to isolate
characteristics.
There was no statistically significant
relationship between the gender or age of the patients and the RFLP
patterns of the isolates. Of 33 clusters, only 6 smaller clusters (two
or three isolates per cluster) represented patients who belonged to the same age group. In general, there was no clear correlation between RFLP
patterns and the geographical origin of the isolates. Thus, the
predominant family A was made of clusters which represent patient
groups from both Northern and Southern part of Estonia (Table
3).
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
In this study we analyzed the drug resistance patterns of the M. tuberculosis isolates from newly detected and culture-verified pulmonary TB patients in Estonia during 1994 in relation to their RFLP patterns obtained with the insertion IS6110 as probe.
This is, to our knowledge, the first time a large group of closely related drug-resistant M. tuberculosis isolates with a limited number of different RFLP banding patterns in a human immunodeficiency virus-(HIV)-negative population has been demonstrated. A high proportion (49%) of all strains tested appeared in clusters. A predominant basic 15- to 19-band RFLP pattern was seen among 29% of all isolates, making up the family A. This family A comprised 12 clusters of identical isolates where the largest cluster comprised 10 identical isolates. The majority of all MDR isolates and isolates with any drug resistance belonged to family A.
A study on the population structure of M. tuberculosis strains in Ethiopia, Tunisia, and The Netherlands suggested that there are a small number of predominant families of genetically related strains in Ethiopia and Tunisia whereas no such distinct groupings predominate in The Netherlands (8, 22). Van Soolingen et al. have reinforced the idea that the predominance success of particular clones is related to a high incidence of TB (21). The current epidemiological situation place Estonia between the high-risk, resource-poor communities (like Ethiopia and Tunisia) and low-risk, developed communities (like The Netherlands).
The investigation of the population structure of M. tuberculosis in Estonia suggests that one-third of the isolates belonged to a remarkably homogeneous family of strains (family A). This family of strains may have contributed to the recent steady increase in TB morbidity since 1992 and, even more importantly, may have contributed to the emergence of MDR TB in the region (24-26).
The high similarity between the drug-resistant isolates indicates that in Estonia these strains are spreading rapidly, in fact more rapidly than the drug-susceptible strains, although the forces that contributed to the selection and dissemination of strains of family A are likely to be multifactorial. One reason for this rapid spread is probably that patients with drug-resistant strains are difficult to cure (19) and therefore will be contagious for a longer period.
In other studies where resistant strains were found in clusters, it was clearly demonstrated that transmission of MDR strains had occurred among HIV-infected patients (2, 16). In 1994, coinfection with tuberculosis and HIV was not reported in Estonia. Transmission of MDR TB is thus not limited to HIV-seropositive patients in an institutional setting but occurs within a community.
The strains included in family A were confirmed by spoligotyping as Beijing genotype strains. Van Soolingen et al. have shown that M. tuberculosis isolates grouped into the Beijing family by their IS6110 fingerprints and spoligopatterns also have a similar grouping pattern when other genetic markers are used. These characteristics are not generally shared with other strains outside the Beijing family (21). Recent observations suggest that strains of the Beijing family constitute a genetically closely related group of bacteria. Strains belonging to this genotype family possibly share particular phenotypic properties, such as antigens and virulence factors, which may be expressed as distinct manifestations in the pathology and the epidemiology of tuberculosis (12).
The Beijing genotype is the predominant clone of M. tuberculosis isolates in China (21), and isolates belonging to the Beijing family have been reported from four continents during the last few years (5, 21). This is the first countrywide study showing a correlation between the Beijing family and drug resistance.
The majority of isolates belonging to family A. i.e., the Beijing family. were drug resistant, but there was heterogeneity in resistance patterns among the isolates, ranging from full susceptibility to resistance to all four drugs tested. Of 12 clusters, 3 small clusters had isolates that were uniformly fully susceptible in their antibiotic resistance pattern. This fact indicates that drug resistance developed recently and in different clones among strains belonging to this family of strains.
Alito et al. have shown that some genotypes of MDR M. tuberculosis strains may have a higher mutation frequency and that the instability of IS6110 RFLP (highly similar but not identical RFLP patterns and with identical spoligotype) may be somehow related to the selective pressure of a combination of drugs used in therapy (1).
In contrast to our findings, Wilson et al. (23) have studied the contribution of recent transmission to the spread of non-Beijing drug-resistant TB in Texas. Based on the low percentage of clustered cases and the small cluster size, the authors concluded that there is no evidence for extensive transmission of drug-resistant TB.
Sources of TB have been suggested to preferentially transmit infection to people close to their own age (3). In the present study, when we analyzed cluster data stratified by age, we found that most of the 33 clusters contained patients of all age groups whereas only 6 smaller clusters comprised patients who belonged to same age group.
In general there was no strict correlation between clones and families with respect to the geographical origin of the isolates. Even if the MDR strains belonged to the same cluster, they were isolated from patients from different geographical areas, indicating that transmission of particular drug-resistant clones of M. tuberculosis contributes to the emergence of drug-resistant TB all over the country.
M. tuberculosis strains belonging to the Beijing genotype family have continued to dominate among new MDR TB patients in Estonia to the present day. There are strong indications that strains belonging to this family are widespread within the former Soviet Union and have even spread other parts of Europe such as Germany (17).
The data obtained during this study will contribute to a more thorough understanding of TB and MDR TB transmission in Estonia. Continued surveillance and immediate therapeutic decisions should be undertaken to prevent the dissemination of TB, and particularly when caused by such resistant strains.
| |
ACKNOWLEDGMENTS |
|---|
We express our gratitude to Marika Mikelsaar for critical reading and fruitful suggestions relating to the manuscript.
The study was supported by the Karolinska International Research and Training Programme, the Swedish Heart-Lung Association, the Swedish Medical Research Council (grant K99-06X), and the Commission of the European Communities, Directorate General XII, contract BMH1-CT93-1614.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Swedish Institute for Infectious Disease Control, Nobels Vag 18, SE-171 82 Solna, Stockholm, Sweden. Phone: 46 8 4572430. Fax: 46 8 301797. E-mail: gunilla.kallenius{at}smi.ki.se.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. |
Alto, A.,
N. Morcillo,
S. Scipioni,
A. Dolmann,
M. I. Romano,
A. Cataldi, and D. van Soolingen.
1999.
The IS6110 restriction fragment length polymorphism in particular multidrug-resistant Mycobacterium tuberculosis strains may evolve too fast for reliable use in outbreak investigation.
J. Clin. Microbiol.
37:788-791 |
| 2. |
Bifani, P. J.,
B. B. Plikaytis,
V. Kapur, et al.
1996.
Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family.
JAMA
275:452-457 |
| 3. | Borgdorff, M. W., N. J. D. Nagelkerke, D. van Soolingen, and J. F. Broekmans. 1999. Transmission of tuberculosis between people of different ages in the Netherlands: an analysis using DNA fingerprinting. Int. J. Tuberc. Lung Dis. 3:202-206[Medline]. |
| 4. | Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A. Mitchison, N. Rist, and N. A. Smeley. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43[Medline]. |
| 5. |
Dale, J. W.,
R. Mat Nor,
S. Ramayah,
T. Hock Tang, and Z. F. Zainuddin.
1999.
Molecular epidemiology of tuberculosis in Malaysia.
J. Clin. Microbiol.
37:1265-1268 |
| 6. | Glynn, J. R., J. Bauer, A. S. de Boer, M. W. Borgdorff, P. E. Fine, P. Godfrey-Faussett, and E. Vynnycky. 1999. Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. European Concerted Action on Molecular Epidemiology and Control of Tuberculosis. Int. J. Tuberc. Lung Dis. 3:1055-1060[Medline]. |
| 7. | Heersma, H. F. K., K. Kremer, and J. D. A. van Embden. 1998. Computer analysis of IS6110 RFLP patterns of Mycobacterium tuberculosis. Methods Mol. Biol. 101:395-422[Medline]. |
| 8. | Hermans, P. W. M., F. Messadi, H. Guebrexabher, D. van Soolingen, P. E. W. de Haas, H. Heersma, H. de Neeling, A. Ayoub, F. Portales, D. Frommel, M. Zribi, and J. D. A. van Embden. 1995. Usefulness of DNA typing for global tuberculosis epidemiology. J. Infect. Dis. 171:1504-1513[Medline]. |
| 9. | Hoffner, S. E., and G. Källenius. 1988. Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin. Eur. J. Clin. Microbiol. Infect. Dis. 7:188-190[CrossRef][Medline]. |
| 10. | Isenberg, H. D. (ed.). 1992. Clinical microbiology procedures handbook, vol. 1. , p. 3.11.1-3.12.27. American Society for Microbiology, Washington, D.C. |
| 11. | Kamerbeek, J., L. Schouls, A. Kolk, M. van Agderveld, D. van Soolingen, S. Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. D. A. van Embden. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914[Abstract]. |
| 12. |
Kremer, K.,
D. van Soolingen,
R. Frothingham,
W. H. Haas,
P. W. M. Hermans,
C. Martin,
P. Palittapongarnpim,
B. B. Plikaytis,
L. W. Riley,
M. A. Yakrus,
M. J. Musser, and J. D. A. van Embden.
1999.
Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility.
J. Clin. Microbiol.
37:2607-2618 |
| 13. | Krüüner, A., H. Sillastu, M. Danilovitsh, K. Levina, S. B. Svenson, G. Källenius, and S. E. Hoffner. 1998. Drug resistant tuberculosis in Estonia. Int. J. Tuberc. Lung Dis. 2:130-133[Medline]. |
| 14. | Kubin, M., M. Havelkova, I. Hyncicova, Z. Svecova, J. Kaustova, K. Kremer, and D. van Soolingen. 2000. The first occurrence of a multi-drug resistant tuberculosis epidemic in the Czech Republic caused by genetically closely related Mycobacterium tuberculosis strains. Centr. Eur. J. Publ. Health. 8:24-27. |
| 15. | Laszlo, A., M. Rahman, M. Raviglione, F. Bustreo, and WHO/IUATLD Network of Supranational Reference Laboratories. 1997. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational laboratory network: first round of proficiency testing. Int. J. Tuberc. Lung Dis. 1:231-238[Medline]. |
| 16. | Moro, M. I., I. Errante, A. Infuso, L. Sodano, A. Gori, C. A. Orcese, G. Salamina, C. D'Amico, G. Besozzi, and L. Caggese. 2000. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int. J. Tuberc. Lung Dis. 4:61-68[Medline]. |
| 17. | Niemann, S., S. Rüsch-Gerdes, and E. Richter. 1997. IS6110 fingerprinting of drug-resistant Mycobacterium tuberculosis strains isolated in Germany during 1995. J. Clin. Microbiol. 35:3015-20[Abstract]. |
| 18. |
Siddiqi, S. H.,
J. P. Libonati, and G. Middlebrook.
1981.
Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.
J. Clin. Microbiol.
13:908-913 |
| 19. | Turett, G. S., E. E. Telzak, L. V. Torian, S. Blum, D. Alland, I. Weisfuse, et al. 1995. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 21:1238-1244[Medline]. |
| 20. |
van Embden, J. D. A.,
M. D. Cave,
J. T. Crawford,
J. W. Dale,
K. D. Eisenach,
B. Gicquel,
P. W. M. Hermans,
C. Martin,
R. McAdam,
T. M. Shinnick, and P. M. Small.
1993.
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.
J. Clin. Microbiol.
31:406-409 |
| 21. | Van Soolingen, D., L. Qian, P. E. W. de Haas, J. T. Douglas, H. Traore, F. Portaels, H. Z. Qing, D. Enkhsaikan, P. Nymadawa, and J. D. A. van Embden. 1995. Predominance of a single genotype of Mycobacterium tuberculosis in countries of East Asia. J. Clin. Microbiol. 33:3234-3238[Abstract]. |
| 22. | Van Soolingen, D., M. W. Borgdorff, P. E. W. de Haas, M. M. G. G. Sebek, J. Veen, M. Dessens, K. Kremer, and J. D. A. van Embden. 1999. Molecular epidemiology of tuberculosis in The Netherlands: a nationwide study from 1993 through 1997. J. Infect. Dis. 180:726-736[CrossRef][Medline]. |
| 23. |
Wilson, R. W.,
Z. Yang,
M. Kelley,
M. D. Cave,
J. M. Pogoda,
R. J. Wallace, Jr.,
J. P. Cegielski,
D. F. Dunbar,
D. Bergmire-Sweat,
L. B. Elliott, and P. F. Barnes.
1999.
Evidence from molecular fingerprinting of limited spread of drug-resistant tuberculosis in Texas.
J. Clin. Microbiol.
37:3255-3259 |
| 24. | World Health Organization. 1997. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1996. WHO/TB/97.229. World Health Organization, Geneva, Switzerland. |
| 25. | World Health Organization. 2000. Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1996-1999. WHO/CDS/TB/2000.278. World Health Organization, Geneva, Switzerland. |
| 26. | World Health Organization. 2000. Global tuberculosis control. WHO report 2000. WHO/CDS/TB/2000.275. World Health Organization, Geneva, Switzerland. |
| 27. |
Yang, Z.,
P. F. Barnes,
F. Chaves,
K. D. Eisenach,
S. E. Weis,
J. H. Bates, and M. D. Cave.
1998.
Diversity of DNA fingerprints of Mycobacterium tuberculosis isolates in the United States.
J. Clin. Microbiol.
36:1003-1007 |
Journal of Clinical Microbiology, September 2001, p. 3339-3345, Vol. 39, No. 9
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.9.3339-3345.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Luciani, F., Sisson, S. A., Jiang, H., Francis, A. R., Tanaka, M. M.
(2009). The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA
106: 14711-14715
[Abstract] [Full Text] -
Stavrum, R., Mphahlele, M., Ovreas, K., Muthivhi, T., Fourie, P. B., Weyer, K., Grewal, H. M. S.
(2009). High Diversity of Mycobacterium tuberculosis Genotypes in South Africa and Preponderance of Mixed Infections among ST53 Isolates. J. Clin. Microbiol.
47: 1848-1856
[Abstract] [Full Text] -
Kliiman, K., Altraja, A.
(2009). Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J
33: 1085-1094
[Abstract] [Full Text] -
Phyu, S., Stavrum, R., Lwin, T., Svendsen, O. S., Ti, T., Grewal, H. M. S.
(2009). Predominance of Mycobacterium tuberculosis EAI and Beijing Lineages in Yangon, Myanmar. J. Clin. Microbiol.
47: 335-344
[Abstract] [Full Text] -
Mokrousov, I., Narvskaya, O., Vyazovaya, A., Millet, J., Otten, T., Vishnevsky, B., Rastogi, N.
(2008). Mycobacterium tuberculosis Beijing Genotype in Russia: in Search of Informative Variable-Number Tandem-Repeat Loci. J. Clin. Microbiol.
46: 3576-3584
[Abstract] [Full Text] -
Iwamoto, T., Yoshida, S., Suzuki, K., Wada, T.
(2008). Population Structure Analysis of the Mycobacterium tuberculosis Beijing Family Indicates an Association between Certain Sublineages and Multidrug Resistance. Antimicrob. Agents Chemother.
52: 3805-3809
[Abstract] [Full Text] -
Lazzarini, L. C. O., Spindola, S. M., Bang, H., Gibson, A. L., Weisenberg, S., da Silva Carvalho, W., Augusto, C. J., Huard, R. C., Kritski, A. L., Ho, J. L.
(2008). RDRio Mycobacterium tuberculosis Infection Is Associated with a Higher Frequency of Cavitary Pulmonary Disease. J. Clin. Microbiol.
46: 2175-2183
[Abstract] [Full Text] -
Drobniewski, F. A., Hoffner, S., Rusch-Gerdes, S., Skenders, G., Thomsen, V., the WHO European Laboratory Strengthening Task For,
(2006). Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J
28: 903-909
[Abstract] [Full Text] -
Kodmon, C., Niemann, S., Lukacs, J., Sor, E., David, S., Somoskovi, A.
(2006). Molecular Epidemiology of Drug-Resistant Tuberculosis in Hungary. J. Clin. Microbiol.
44: 4258-4261
[Abstract] [Full Text] -
Kim, H. J., Kang, C. H., Kim, Y. T., Sung, S-W., Kim, J. H., Lee, S. M., Yoo, C-G., Lee, C-T., Kim, Y. W., Han, S. K., Shim, Y-S., Yim, J-J.
(2006). Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J
28: 576-580
[Abstract] [Full Text] -
Kruuner, A., Yates, M. D., Drobniewski, F. A.
(2006). Evaluation of MGIT 960-Based Antimicrobial Testing and Determination of Critical Concentrations of First- and Second-Line Antimicrobial Drugs with Drug-Resistant Clinical Strains of Mycobacterium tuberculosis.. J. Clin. Microbiol.
44: 811-818
[Abstract] [Full Text] -
Wootton, S. H., Gonzalez, B. E., Pawlak, R., Teeter, L. D., Smith, K. C., Musser, J. M., Starke, J. R., Graviss, E. A.
(2005). Epidemiology of Pediatric Tuberculosis Using Traditional and Molecular Techniques: Houston, Texas. Pediatrics
116: 1141-1147
[Abstract] [Full Text] -
Lavender, C., Globan, M., Sievers, A., Billman-Jacobe, H., Fyfe, J.
(2005). Molecular Characterization of Isoniazid-Resistant Mycobacterium tuberculosis Isolates Collected in Australia. Antimicrob. Agents Chemother.
49: 4068-4074
[Abstract] [Full Text] -
Hazbon, M. H., Bobadilla del Valle, M., Guerrero, M. I., Varma-Basil, M., Filliol, I., Cavatore, M., Colangeli, R., Safi, H., Billman-Jacobe, H., Lavender, C., Fyfe, J., Garcia-Garcia, L., Davidow, A., Brimacombe, M., Leon, C. I., Porras, T., Bose, M., Chaves, F., Eisenach, K. D., Sifuentes-Osornio, J., Ponce de Leon, A., Cave, M. D., Alland, D.
(2005). Role of embB Codon 306 Mutations in Mycobacterium tuberculosis Revisited: a Novel Association with Broad Drug Resistance and IS6110 Clustering Rather than Ethambutol Resistance. Antimicrob. Agents Chemother.
49: 3794-3802
[Abstract] [Full Text] -
Gazouli, M., Ikonomopoulos, J., Koundourakis, A., Bartos, M., Pavlik, I., Overduin, P., Kremer, K., Gorgoulis, V., Kittas, C.
(2005). Characterization of Mycobacterium tuberculosis Complex Isolates from Greek Patients with Sarcoidosis by Spoligotyping. J. Clin. Microbiol.
43: 4858-4861
[Abstract] [Full Text] -
Drobniewski, F. A., Balabanova, Y. M., Ruddy, M. C., Graham, C., Kuznetzov, S. I., Gusarova, G. I., Zakharova, S. M., Melentyev, A. S., Fedorin, I. M.
(2005). Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners. Eur Respir J
26: 298-304
[Abstract] [Full Text] -
Drobniewski, F., Balabanova, Y., Nikolayevsky, V., Ruddy, M., Kuznetzov, S., Zakharova, S., Melentyev, A., Fedorin, I.
(2005). Drug-Resistant Tuberculosis, Clinical Virulence, and the Dominance of the Beijing Strain Family in Russia. JAMA
293: 2726-2731
[Abstract] [Full Text] -
Baker, L. V., Brown, T. J., Maxwell, O., Gibson, A. L., Fang, Z., Yates, M. D., Drobniewski, F. A.
(2005). Molecular Analysis of Isoniazid-Resistant Mycobacterium tuberculosis Isolates from England and Wales Reveals the Phylogenetic Significance of the ahpC -46A Polymorphism. Antimicrob. Agents Chemother.
49: 1455-1464
[Abstract] [Full Text] -
Jou, R., Chiang, C.-Y., Huang, W.-L.
(2005). Distribution of the Beijing Family Genotypes of Mycobacterium tuberculosis in Taiwan. J. Clin. Microbiol.
43: 95-100
[Abstract] [Full Text] -
Kam, K. M., Yip, C. W., Tse, L. W., Wong, K. L., Lam, T. K., Kremer, K., Au, B. K. Y., van Soolingen, D.
(2005). Utility of Mycobacterial Interspersed Repetitive Unit Typing for Differentiating Multidrug-Resistant Mycobacterium tuberculosis Isolates of the Beijing Family. J. Clin. Microbiol.
43: 306-313
[Abstract] [Full Text] -
Nikolayevsky, V., Brown, T., Balabanova, Y., Ruddy, M., Fedorin, I., Drobniewski, F.
(2004). Detection of Mutations Associated with Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Isolates from Samara Region, Russian Federation. J. Clin. Microbiol.
42: 4498-4502
[Abstract] [Full Text] -
Kremer, K., Glynn, J. R., Lillebaek, T., Niemann, S., Kurepina, N. E., Kreiswirth, B. N., Bifani, P. J., van Soolingen, D.
(2004). Definition of the Beijing/W Lineage of Mycobacterium tuberculosis on the Basis of Genetic Markers. J. Clin. Microbiol.
42: 4040-4049
[Abstract] [Full Text] -
Brudey, K., Gordon, M., Mostrom, P., Svensson, L., Jonsson, B., Sola, C., Ridell, M., Rastogi, N.
(2004). Molecular Epidemiology of Mycobacterium tuberculosis in Western Sweden. J. Clin. Microbiol.
42: 3046-3051
[Abstract] [Full Text] -
Barnes, P. F., Cave, M. D.
(2003). Molecular Epidemiology of Tuberculosis. NEJM
349: 1149-1156
[Full Text] -
Werngren, J., Hoffner, S. E.
(2003). Drug-Susceptible Mycobacterium tuberculosis Beijing Genotype Does Not Develop Mutation-Conferred Resistance to Rifampin at an Elevated Rate. J. Clin. Microbiol.
41: 1520-1524
[Abstract] [Full Text] -
Puustinen, K., Marjamaki, M., Rastogi, N., Sola, C., Filliol, I., Ruutu, P., Holmstrom, P., Viljanen, M. K., Soini, H.
(2003). Characterization of Finnish Mycobacterium tuberculosis Isolates by Spoligotyping. J. Clin. Microbiol.
41: 1525-1528
[Abstract] [Full Text] -
Burgos, M.V., Pym, A.S.
(2002). Molecular epidemiology of tuberculosis. Eur Respir J
20: 54S-65s
[Abstract] [Full Text] -
Toungoussova, O. S., Sandven, P., Mariandyshev, A. O., Nizovtseva, N. I., Bjune, G., Caugant, D. A.
(2002). Spread of Drug-Resistant Mycobacterium tuberculosis Strains of the Beijing Genotype in the Archangel Oblast, Russia. J. Clin. Microbiol.
40: 1930-1937
[Abstract] [Full Text] -
Dye, C., Williams, B. G., Espinal, M. A., Raviglione, M. C.
(2002). Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. Science
295: 2042-2046
[Abstract] [Full Text] -
Qian, L., Abe, C., Lin, T.-P., Yu, M.-C., Cho, S.-N., Wang, S., Douglas, J. T.
(2002). rpoB Genotypes of Mycobacterium tuberculosis Beijing Family Isolates from East Asian Countries. J. Clin. Microbiol.
40: 1091-1094
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»